Neuromyelitis optica spectrum disorder is a severe autoimmune astrogliopathy targeting the central nervous system. Recurrent attacks of longitudinally extensive transverse myelitis frequently inflict permanent motor, sensory, and autonomic deficits. Recent clinical investigations have emphasized measuring spinal cord atrophy NMOSD to evaluate chronic tissue destruction beyond acute relapse episodes. Understanding these structural dynamics helps clinicians distinguish attack-related loss from silent, insidious neurodegeneration. Furthermore, evaluating targeted immunotherapies provides crucial insight into preserving long-term neurological function and preventing physical disability.

Mechanisms Driving Spinal Cord Atrophy NMOSD

Neuromyelitis optica spectrum disorder primarily involves immune-mediated attacks against aquaporin-4 water channels on astrocyte end-feet. Consequently, intense complement activation and inflammatory infiltration trigger secondary oligodendrocyte death and profound axonal transection. Longitudinally extensive transverse myelitis causes severe necrotic tissue cavitation across multiple contiguous vertebral segments. Over time, these focal destructive lesions evolve into permanent structural loss.

However, investigators have questioned whether cord thinning occurs exclusively during symptomatic relapses. Recent longitudinal observations demonstrate that neurodegenerative processes may continue smoldering even during clinical remission. Chronic microglial activation and trans-synaptic degeneration contribute significantly to sustained axonal loss. Additionally, persistent subclinical inflammation impedes endogenous remyelination and structural repair. Because cord injury dictates ambulatory outcomes, quantifying structural changes is vital. Therefore, tracking tissue loss offers critical insights into the underlying pace of disease progression.

Methodology and Volumetric Imaging Metrics

Accurate assessment of cord dimensions requires standardized, reproducible neuroimaging protocols. Researchers analyzed high-resolution three-dimensional sagittal T1-weighted brain magnetic resonance imaging scans covering the upper cervical cord. Specifically, the C1 through C3 vertebral levels provide accessible landmarks within routine cranial imaging. Investigators utilized the Spinal Cord Toolbox to calculate critical structural parameters automatically.

These computational measurements included cross-sectional area, anteroposterior diameter, and right-left diameter. To ensure objective comparisons, the authors established normative reference values from more than two thousand healthy individuals. Consequently, raw morphometric values were converted into age- and sex-adjusted deviation Z-scores. This sophisticated standardization effectively isolates disease-specific thinning from normal physiological aging. Furthermore, investigators employed linear mixed-effects models to estimate annualized atrophy rates across serial longitudinal scans. Ultimately, combining semi-automated cord segmentation with normative modeling establishes a reliable framework for detecting subtle cord loss over extended observation periods.

Longitudinal Cord Loss and Clinical Progression

The longitudinal cohort study evaluated seventy-two patients with neuromyelitis optica spectrum disorder across two hundred thirty-three MRI scans. Over the observation period, patients exhibited a marked annualized cross-sectional area reduction of approximately negative 0.27 per year. In contrast, healthy individuals maintained stable cord dimensions over comparable intervals. This divergence underscores the destructive neurodegenerative burden imposed by recurrent neuroinflammatory attacks.

Moreover, structural thinning extended across both anteroposterior and transverse cord dimensions. Reductions in cord volume correlated significantly with accumulated physical impairment measured on the Expanded Disability Status Scale. Patients with a prior history of severe transverse myelitis demonstrated the most substantial tissue reduction. Notably, focal cord destruction translated into generalized cervical thinning over time. Repeated inflammatory episodes clearly accelerated tissue loss, but cord shrinkage also continued during relapse-free intervals. Consequently, insidious secondary neurodegeneration appears to progress continuously following severe initial autoimmune insults.

Therapeutic Impact of Rituximab Maintenance

B-cell depletion therapy with rituximab represents a cornerstone of disease maintenance in neuromyelitis optica spectrum disorder. The study comprehensively examined how rituximab administration influenced annualized spinal cord atrophy rates over long-term observation. Notably, patients receiving regular rituximab infusions demonstrated significant attenuation of structural cord loss compared to untreated intervals.

This therapeutic benefit arises primarily from preventing subsequent autoimmune attacks on astrocytic foot processes. By eliminating CD20-positive B cells, rituximab suppresses pathogenic autoantibody production and halts complement-mediated cytotoxicity. Consequently, patients on sustained rituximab therapy avoid the devastating parenchymal necrosis seen in recurrent myelitis. Furthermore, stabilizing the blood-spinal cord barrier minimizes chronic microglial activation and subsequent bystander neuroaxonal degeneration. Importantly, the data suggest that early therapeutic initiation provides superior neuroprotective outcomes. When clinicians institute B-cell depletion promptly after initial presentation, they preserve vital spinal cord parenchyma before irreversible atrophy occurs.

Clinical Biomarkers and Indian Practice Implications

In addition to neuroimaging, fluid biomarkers provide indispensable insights into real-time biological disease activity. Circulating concentrations of neurofilament light chain reflect acute neuroaxonal breakdown, whereas glial fibrillary acidic protein marks severe astrocytic injury. Longitudinal analyses revealed that elevated biomarker levels correlated significantly with accelerated cervical cord atrophy rates. Specifically, patients displaying persistent biomarker elevations suffered faster structural cord thinning over serial follow-up.

These findings carry immense clinical significance for neurological practice across India. In Indian clinical settings, neuromyelitis optica spectrum disorder accounts for a substantial proportion of non-traumatic myelopathies. Because novel biologics remain financially prohibitive for many families, rituximab serves as the primary standard of care. Brain magnetic resonance imaging protocols often include the upper cervical spine through the C3 segment. Therefore, Indian radiologists and neurologists can opportunistically quantify upper cord cross-sectional area without ordering separate spinal acquisitions. Ultimately, optimizing rituximab protocols and monitoring upper cervical cord dimensions will enhance long-term functional independence and reduce disability.

Frequently Asked Questions

How does rituximab slow neurodegeneration in NMOSD?

Rituximab depletes CD20-positive B lymphocytes, halting the downstream production of pathogenic aquaporin-4 antibodies. Consequently, this targeted therapy suppresses complement activation and secondary astrocytic destruction. By preventing recurrent inflammatory myelitis attacks, rituximab mitigates cumulative axonal loss and markedly slows the progression of irreversible cervical cord atrophy over long-term follow-up.

Why is measuring C1-C3 cord area clinically significant?

Upper cervical cross-sectional area serves as a sensitive neuroimaging surrogate for cumulative neuroaxonal injury. Standard brain MRI protocols routinely capture C1-C3 segments, enabling efficient longitudinal surveillance without requiring separate spinal cord acquisition. Therefore, monitoring volumetric changes at these levels allows clinicians to track subclinical progression and evaluate therapeutic response reliably over time.

What role do serum NfL and GFAP play in tracking disease?

Serum neurofilament light chain reflects neuroaxonal breakdown, whereas glial fibrillary acidic protein marks severe astrocytic injury characteristic of aquaporin-4 astrogliopathy. Together, these circulating biomarkers correlate with acute inflammatory exacerbations and longitudinal tissue loss. Accordingly, combining fluid biomarkers with serial neuroimaging provides clinicians with objective markers of silent neurodegeneration in routine clinical practice.

Disclaimer: This content is for informational and educational purposes only. It is not intended to provide medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Refer to the latest local and national guidelines for clinical practice.

References

1. Yao Y et al. Longitudinal Spinal Cord Atrophy in Patients With Neuromyelitis Optica Spectrum Disorder and Its Association With Rituximab Treatment. Neurology. 2026 Jun 23. doi: 10.1212/WNL.0000000000218120. PMID: 42224638.


2. Chien C, Papazoglou S, Scheel M, et al. Spinal Cord Atrophy in Neuromyelitis Optica Spectrum Disorders Is Spatially Related to Cord Lesions and Disability. Radiology. 2020;296(3):616-624.


3. Damato V, Evoli A, Iorio R. Efficacy and safety of rituximab therapy in neuromyelitis optica spectrum disorders: A systematic review and meta-analysis. JAMA Neurol. 2016;73(11):1342-1348.